iTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Ansbert Gadicke Sells 60,808 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Ansbert Gadicke sold 60,808 shares of the company’s stock in a transaction that occurred on Wednesday, November 24th. The shares were sold at an average price of $36.29, for a total value of $2,206,722.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

  • On Monday, November 22nd, Ansbert Gadicke sold 35,333 shares of iTeos Therapeutics stock. The shares were sold at an average price of $37.52, for a total value of $1,325,694.16.
  • On Monday, September 13th, Ansbert Gadicke sold 35,785 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.64, for a total value of $989,097.40.
  • On Thursday, September 9th, Ansbert Gadicke sold 38,028 shares of iTeos Therapeutics stock. The stock was sold at an average price of $28.97, for a total value of $1,101,671.16.
  • On Tuesday, September 7th, Ansbert Gadicke sold 50,996 shares of iTeos Therapeutics stock. The stock was sold at an average price of $29.18, for a total value of $1,488,063.28.

Shares of ITOS opened at $36.98 on Thursday. The company’s fifty day simple moving average is $29.02. iTeos Therapeutics, Inc. has a 12 month low of $17.43 and a 12 month high of $47.61. The stock has a market cap of $1.30 billion, a P/E ratio of 127.52 and a beta of 1.94.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Wednesday, November 10th. The company reported $1.86 EPS for the quarter, missing the consensus estimate of $4.95 by ($3.09). During the same quarter last year, the firm posted ($0.48) earnings per share. Research analysts forecast that iTeos Therapeutics, Inc. will post 4.64 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of ITOS. Goldman Sachs Group Inc. boosted its stake in iTeos Therapeutics by 9.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 66,551 shares of the company’s stock valued at $2,275,000 after purchasing an additional 5,892 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of iTeos Therapeutics by 128.7% during the 1st quarter. Nuveen Asset Management LLC now owns 125,772 shares of the company’s stock valued at $4,299,000 after buying an additional 70,784 shares during the period. Royal Bank of Canada lifted its holdings in shares of iTeos Therapeutics by 532.1% during the 1st quarter. Royal Bank of Canada now owns 1,732 shares of the company’s stock valued at $59,000 after buying an additional 1,458 shares during the period. California State Teachers Retirement System lifted its holdings in shares of iTeos Therapeutics by 75.7% during the 1st quarter. California State Teachers Retirement System now owns 29,767 shares of the company’s stock valued at $1,017,000 after buying an additional 12,823 shares during the period. Finally, Jane Street Group LLC bought a new position in iTeos Therapeutics in the 1st quarter worth $381,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

Several analysts recently weighed in on ITOS shares. SVB Leerink cut their price target on iTeos Therapeutics from $55.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, November 12th. Zacks Investment Research downgraded iTeos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Piper Sandler cut their price target on iTeos Therapeutics from $50.00 to $42.00 and set an “overweight” rating on the stock in a research note on Thursday, November 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $43.80.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

See Also: What is the Producer Price Index (PPI)?

Insider Buying and Selling by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.